Patents by Inventor Aleksandar Filip Radovic-Moreno

Aleksandar Filip Radovic-Moreno has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
    Patent number: 11957788
    Abstract: Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: April 16, 2024
    Assignee: Exicure Operating Company
    Inventors: Aleksandar Filip Radovic-Moreno, Richard Kang, Subbarao Nallagatla, Christopher C. Mader, Sergei Gryaznov
  • Genetically engineered hematopoietic stem cells and uses thereof
    Patent number: 11903973
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: February 16, 2021
    Date of Patent: February 20, 2024
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF
    Publication number: 20230053285
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: May 31, 2022
    Publication date: February 16, 2023
    Applicant: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Genetically engineered hematopoietic stem cells and uses thereof
    Patent number: 11571445
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: February 7, 2023
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Genetically engineered hematopoietic stem cells and uses thereof
    Patent number: 11559551
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: January 24, 2023
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Genetically engineered hematopoietic stem cells and uses thereof
    Patent number: 11464807
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: October 11, 2022
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • MULTIVALENT DELIVERY OF IMMUNE MODULATORS BY LIPOSOMAL SPHERICAL NUCLEIC ACIDS FOR PROPHYLACTIC OR THERAPEUTIC APPLICATIONS
    Publication number: 20220257512
    Abstract: Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.
    Type: Application
    Filed: August 18, 2021
    Publication date: August 18, 2022
    Applicant: Exicure Operating Company
    Inventors: Aleksandar Filip Radovic-Moreno, Richard Kang, Subbarao Nallagatla, Christopher C. Mader, Sergei Gryaznov
  • Genetically engineered hematopoietic stem cells and uses thereof
    Patent number: 11389485
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: July 19, 2022
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Genetically engineered hematopoietic stem cells and uses thereof
    Patent number: 11382932
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: July 12, 2022
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF
    Publication number: 20220008476
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: February 16, 2021
    Publication date: January 13, 2022
    Applicant: VOR BIOPHARMA, INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF
    Publication number: 20210315936
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: April 5, 2021
    Publication date: October 14, 2021
    Applicant: VOR BIOPHARMA, INC
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
    Patent number: 11123294
    Abstract: Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: September 21, 2021
    Assignee: Exicure Operating Company
    Inventors: Aleksandar Filip Radovic-Moreno, Richard Kang, Subbarao Nallagatla, Christopher C. Mader, Sergei Gryaznov
  • GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF
    Publication number: 20210236559
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: April 5, 2021
    Publication date: August 5, 2021
    Applicant: VOR BIOPHARMA, INC
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF
    Publication number: 20210228641
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: April 5, 2021
    Publication date: July 29, 2021
    Applicant: VOR BIOPHARMA, INC
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF
    Publication number: 20210220407
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: April 5, 2021
    Publication date: July 22, 2021
    Applicant: VOR BIOPHARMA, INC
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • SPHERICAL NUCLEIC ACID-BASED CONSTRUCTS AS IMMUNOSTIMULATORY AGENTS FOR PROPHYLACTIC AND THERAPEUTIC USE
    Publication number: 20210102211
    Abstract: Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof.
    Type: Application
    Filed: October 8, 2020
    Publication date: April 8, 2021
    Applicant: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Christopher C. Mader, Subbarao Nallagatla, Warefta Hasan, Aaron Love, Sergei Gryaznov
  • Genetically engineered hematopoietic stem cells and uses thereof
    Patent number: 10925902
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: February 23, 2021
    Assignee: VOR BIOPHARMA, INC
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
    Patent number: 10894963
    Abstract: Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: January 19, 2021
    Assignee: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Christopher C. Mader, Subbarao Nallagatla, Warefta Hasan, Aaron Love, Sergei Gryaznov
  • Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
    Patent number: 10837018
    Abstract: Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof. The compositions of the invention are useful for activating agonists of nucleic acid interacting complexes, such as TLRs, stimulating an immune response, and treating diseases such as infectious disease, cancer, allergies, allergic diseases, and autoimmune disease.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: November 17, 2020
    Assignee: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Christopher C. Mader, Subbarao Nallagatla, Warefta Hasan, Aaron Love, Sergei Gryaznov
  • GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF
    Publication number: 20200338130
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: August 28, 2019
    Publication date: October 29, 2020
    Applicants: VOR BIOPHARMA, INC, PureTech Management, Inc.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard